Alchemab Therapeutics · Series A

UK biotech using machine learning to mine patient-derived immune responses for protective

Amount

$32M

Round

Series A

Valuation

—

Announced

—

Investors

Participating investors

Eli Lilly DCVC Bio Ono Venture Investment RA Capital SV Health Investors Lightstone Ventures